Skip to main content
SpringerLink
Log in

Hydroxyethyl starch: putting patient safety first

  • What's New in Intensive Care
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L (2001) Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 357:911–916

    Article  CAS  PubMed  Google Scholar 

  2. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358:125–139

    Article  CAS  PubMed  Google Scholar 

  3. Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S (2013) Fluid resuscitation with 6 % hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 39:558–568

    Article  CAS  PubMed  Google Scholar 

  4. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA (2012) Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367:1901–1911

    Article  CAS  PubMed  Google Scholar 

  5. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J (2013) Hydroxyethyl starch 130/0.38–0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 346:839

    Article  Google Scholar 

  6. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, Madsen KR, Moller MH, Elkjaer JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Soe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjaeldgaard AL, Fabritius ML, Mondrup F, Pott FC, Moller TP, Winkel P, Wetterslev J (2012) Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 367:124–134

    Article  CAS  PubMed  Google Scholar 

  7. Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, Fergusson DA (2013) Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 309:678–688

    Article  CAS  PubMed  Google Scholar 

  8. European Medicines Agency (EMA) (2013) Press release: European Medicines Agency (EMA) PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl-starch. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001814.jsp&mid=WC0b01ac058004d5c1. Accessed 12 Nov 2013

  9. European Medicines Agency (EMA) (2013) Press Release: European Medicines Agency (EMA) PRAC confirms that hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Solutions_for_infusion_containing_hydroxyethyl_starch/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500151963.pdf. Accessed 12 Nov 2013

  10. European Medicines Agency (EMA) (2013) Press Release: Hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients—CMDh endorses PRAC recommendations. EMA/640658/2013. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/10/news_detail_001930.jsp&mid=WC0b01ac058004d5c1. Accessed 12 Nov 2013

  11. Annane D, Siami S, Jaber S, Martin C, Elatrous S, Declere AD, Preiser JC, Outin H, Troche G, Charpentier C, Trouillet JL, Kimmoun A, Forceville X, Darmon M, Lesur O, Regnier J, Abroug F, Berger P, Clech C, Cousson J, Thibault L, Chevret S, for the CI (2013) Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. JAMA 310:1809–1817. doi:10.1001/jama.2013.280502

    Article  CAS  PubMed  Google Scholar 

  12. Ludwig-Maximilians–University of Munich (2010) Klinisches Register RaftinG—Rational Fluid Therapy in Germany (Protocol). Available at: http://clinicaltrials.gov/show/NCT01122277

  13. University Hospital, Basel, Switzerland (2006) Basel Study for Evaluation of Starch (130; 0.4) Infusion in Septic Patients: BaSES (130; 0.4) Trial (Protocol). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00273728

  14. Jonville-Bera AP, Autret-Leca E, Gruel Y (2001) Acquired type I von Willebrand’s disease associated with highly substituted hydroxyethyl starch. N Engl J Med 345:622–623

    Article  CAS  PubMed  Google Scholar 

  15. Hartog CS, Reuter D, Loesche W, Hofmann M, Reinhart K (2011) Influence of hydroxyethyl starch (HES) 130/0.4 on hemostasis as measured by viscoelastic device analysis: a systematic review. Intensive Care Med 37:1725–1737

    Article  CAS  PubMed  Google Scholar 

  16. Hecht-Dolnik M, Barkan H, Taharka A, Loftus J (2009) Hetastarch increases the risk of bleeding complications in patients after off-pump coronary bypass surgery: a randomized clinical trial. J Thorac Cardiovasc Surg 138:703–711

    Article  PubMed  Google Scholar 

  17. Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, Oswald E, Bach C, Schnapka-Koepf M, Innerhofer P (2007) Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration. Anesth Analg 105:905–917

    Article  CAS  PubMed  Google Scholar 

  18. Navickis RJ, Haynes GR, Wilkes MM (2012) Effect of hydroxyethyl starch on bleeding after cardiopulmonary bypass: a meta-analysis of randomized trials. J Thorac Cardiovasc Surg 144:223–230

    Article  CAS  PubMed  Google Scholar 

  19. Rasmussen KC, Johansson PI, Hojskov M, Kridina I, Kistorp T, Thind P, Nielsen HB, Ruhnau B, Pedersen T, Secher NH (2013) Hydroxyethyl starch reduces coagulation competence and increases blood loss during major surgery: results from a randomized controlled trial. Ann Surg. doi:10.1097/SLA.0000000000000267

    PubMed  Google Scholar 

  20. James MF, Michell WL, Joubert IA, Nicol AJ, Navsaria PH, Gillespie RS (2011) Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (fluids in resuscitation of severe trauma). Br J Anaesth 107:693–702

    Article  CAS  PubMed  Google Scholar 

  21. Haase N, Wetterslev J, Winkel P, Perner A (2013) Bleeding and risk of death with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial. Intensive Care Med. doi:10.1007/s00134-013-3111-9

    Google Scholar 

  22. Bellomo R, Bion J, Finfer S, Myburgh J, Perner A, Reinhart K (2013) Open Letter. Brit J Anaesth (in press)

  23. Bellomo R, Bion J, Finfer S, Myburgh J, Perner A, Reinhart K (2013) Open Letter. Acta Scand Anaesthesiol (in press)

  24. Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, Forceville X, Feissel M, Hasselmann M, Heininger A, Van Aken H (2012) Assessment of hemodynamic efficacy and safety of 6 % hydroxyethylstarch 130/0.4 vs. 0.9 % NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care 16(3):R94

    Article  PubMed  Google Scholar 

  25. Hartog CS, Reinhart K (2012) CRYSTMAS study adds to concerns about renal safety and increased mortality in sepsis patients. Crit Care 16(6):454. http://ccforum.com/content/16/6/454

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

J Bion: Chair of Data Safety Monitoring Board for International Study of Dexmedetomidine for Orion 2008–2009; honoraria paid to hospital charity. Member of scientific advisory board for Nestle; honoraria (if any) to be paid to hospital charity. Research grants from Health Foundation; NIHR Health Services Research & Delivery Programme; NIHR Research for patient Benefit Programme; EU Leonardo Programme.

R Bellomo: Consultancy fees from Gambro, Baxter and Philips Medical.

John Myburgh: Travel support vian The George Institute for Global Health, Sydney, Australia, this author’s institution, from Fresenius Kabi in relation to the development and conduct of an investigator-initiated randomised-controlled trial (the Crystalloid vs. Hydroxyethyl Starch Trial) and travel expenses and honoraria from Baxter in relation to participation on advisory boards.

Anders Perner: Funding for research from Fresenius Kabi, B Braun AG, CSL Behring, Cosmed and BioPorto A/S. Speakers fee from LBP SA.

Konrad Reinhart: Unpaid Chairman of the Global Sepsis Alliance. B Braun AG and CSL Behring are sponsors of the Global Sepsis Alliance and of World Sepsis Day.

Simon Finfer: Travel support and grant support to his institution (The George Institute for Global Health through the University of Sydney) from Fresenius Kabi, and travel support and advisory fees to his institution (The George Institute for Global Health) from Baxter and CSL Behring.

Author information

Authors and Affiliations

  1. University of Birmingham, Birmingham, UK

    Julian Bion

  2. University of Melbourne, Melbourne, Australia

    Rinaldo Bellomo

  3. The George Institute for Global Health and the University of New South Wales, Sydney, Australia

    John Myburgh

  4. Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

    Anders Perner

  5. Friedrich Schiller University, Jena, Germany

    Konrad Reinhart

  6. Royal North Shore Hospital and The George Institute for Global Health, University of Sydney, Sydney, Australia

    Simon Finfer

Authors
  1. Julian Bion
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rinaldo Bellomo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Myburgh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anders Perner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Konrad Reinhart
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Simon Finfer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julian Bion.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bion, J., Bellomo, R., Myburgh, J. et al. Hydroxyethyl starch: putting patient safety first. Intensive Care Med 40, 256–259 (2014). https://doi.org/10.1007/s00134-013-3167-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-013-3167-6

Keywords

Search

Navigation